Polaryx Therapeutics Announces SOTERIA Trial Launch for PLX-200 in Krabbe Disease

Reuters

02/10

Polaryx <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces SOTERIA Trial Launch for PLX-200 in Krabbe Disease

Polaryx Therapeutics Inc. has announced the upcoming launch of the SOTERIA trial, a clinical study to further evaluate PLX-200, an investigational therapy for Krabbe disease and other lysosomal storage disorders (LSDs). The company presented new preclinical data on PLX-200 at the 22nd Annual WORLDSymposium™ on February 6, 2026, in San Diego. The findings demonstrated that orally administered gemfibrozil, the active compound in PLX-200, promoted anti-inflammatory gene expression and reduced neuro-inflammation in a mouse model of Krabbe disease. The SOTERIA trial is expected to begin in the first half of 2026, following a safe-to-proceed letter from the FDA received in October 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651725) on February 10, 2026, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2610623964"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610623964\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610623964?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610623964","market":"fut","top_or_hot":-1,"title":"Polaryx Therapeutics Announces SOTERIA Trial Launch for PLX-200 in Krabbe Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Polaryx <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces SOTERIA Trial Launch for PLX-200 in Krabbe Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PLYX\">Polaryx Therapeutics Inc</a>. has announced the upcoming launch of the SOTERIA trial, a clinical study to further evaluate PLX-200, an investigational therapy for Krabbe disease and other lysosomal storage disorders (LSDs). The company presented new preclinical data on PLX-200 at the 22nd Annual WORLDSymposium™ on February 6, 2026, in San Diego. The findings demonstrated that orally administered gemfibrozil, the active compound in PLX-200, promoted anti-inflammatory gene expression and reduced neuro-inflammation in a mouse model of Krabbe disease. The SOTERIA trial is expected to begin in the first half of 2026, following a safe-to-proceed letter from the FDA received in October 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651725) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Polaryx Therapeutics Announces SOTERIA Trial Launch for PLX-200 in Krabbe Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPolaryx Therapeutics Announces SOTERIA Trial Launch for PLX-200 in Krabbe Disease\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-10 21:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Polaryx <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces SOTERIA Trial Launch for PLX-200 in Krabbe Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/PLYX\">Polaryx Therapeutics Inc</a>. has announced the upcoming launch of the SOTERIA trial, a clinical study to further evaluate PLX-200, an investigational therapy for Krabbe disease and other lysosomal storage disorders (LSDs). The company presented new preclinical data on PLX-200 at the 22nd Annual WORLDSymposium™ on February 6, 2026, in San Diego. The findings demonstrated that orally administered gemfibrozil, the active compound in PLX-200, promoted anti-inflammatory gene expression and reduced neuro-inflammation in a mouse model of Krabbe disease. The SOTERIA trial is expected to begin in the first half of 2026, following a safe-to-proceed letter from the FDA received in October 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651725) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014005.SGD","symbol_name":"United Global Durable Equities Fund Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLb6MH49:1","article_id":"2610623964","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610623964","pubTimestamp":1770730253,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Polaryx Therapeutics Inc. has announced the upcoming launch of the SOTERIA trial, a clinical study to further evaluate PLX-200, an investigational therapy for Krabbe disease and other lysosomal storage disorders . The company presented new preclinical data on PLX-200 at the 22nd Annual WORLDSymposium on February 6, 2026, in San Diego. The findings demonstrated that orally administered gemfibrozil, the active compound in PLX-200, promoted anti-inflammatory gene expression and reduced neuro-inflammation in a mouse model of Krabbe disease. The SOTERIA trial is expected to begin in the first half of 2026, following a safe-to-proceed letter from the FDA received in October 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therape","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","PLYX":"Polaryx Therapeutics, Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4585":"ETF&股票定投概念","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","BK4112":"金融交易所和数据"},"translate_title":"Polaryx Therapeutics宣布启动PLX-200治疗克拉贝病的SOTERIA试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PLYX":0.9},"content_text":"Polaryx Therapeutics Announces SOTERIA Trial Launch for PLX-200 in Krabbe Disease\n    \n\nPolaryx Therapeutics Inc. has announced the upcoming launch of the SOTERIA trial, a clinical study to further evaluate PLX-200, an investigational therapy for Krabbe disease and other lysosomal storage disorders (LSDs). The company presented new preclinical data on PLX-200 at the 22nd Annual WORLDSymposium™ on February 6, 2026, in San Diego. The findings demonstrated that orally administered gemfibrozil, the active compound in PLX-200, promoted anti-inflammatory gene expression and reduced neuro-inflammation in a mouse model of Krabbe disease. The SOTERIA trial is expected to begin in the first half of 2026, following a safe-to-proceed letter from the FDA received in October 2025.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9651725) on February 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}